Brian Kilen (@briankilen)
Activity by Brian Kilen
Collaboration to support medical innovation, improvements in patient care and the economy
Ireland — Mayo Clinic today announced a five-year collaboration with Enterprise Ireland, the Irish enterprise development agency, to advance novel medical technologies originating from Mayo Clinic. The announcement was made this morning in Dublin by An Taoiseach Enda Kenny T.D., the prime minister of Ireland, at the Medical Device 360° conference.
Journalists: B-roll and sound bites with Mayo and Enterprise leaders are available in the downloads.
This is a unique collaboration providing an alternative source of funding for translational medical research, especially significant at a time when U.S. funding for research is challenging to obtain. Enterprise Ireland has committed up to $16 million in the agreement.
“This collaboration bridges a financial gap for translational research,” says Greg Gores, M.D. , executive dean for research at Mayo Clinic. “It provides funding in between the early-stage basic research and the stage when a technology is ready for the marketplace. In the U.S., this stage is expensive and difficult to fund. We are providing the technologies and Enterprise Ireland the funding. Both of us are contributing to technology advancement.”
The novel medical technologies are Mayo Clinic innovations that have the potential to make it easier for patients to be diagnosed or treated. The development of one technology is already underway at National University of Ireland, Galway (NUI.G). The inventor, Vijay Singh, M.B.B.S., a gastroenterologist at Mayo Clinic in Arizona, developed a device to treat acute pancreatitis, a disease in which the pancreas is rapidly damaged, causing excruciating pain and often resulting in prolonged hospitalization or sometimes death. Experts at NUI.G are currently preparing the device for human clinical trials, which will be conducted by the university.
ROCHESTER, Minn. — March 20, 2014 — Is irritable bowel syndrome (IBS) caused by genetics, diet, past trauma, anxiety? All are thought to play a role, but now, for the first time, researchers have reported a defined genetic defect that causes a subset of IBS. The research was published in the journal Gastroenterology.
Researchers estimate that approximately 15 to 20 percent of the Western world has IBS. It is a common disorder that affects the large intestine. Most patients with the disorder commonly experience symptoms of cramping, abdominal pain, bloating gas, diarrhea and constipation. Most treatments for IBS target these symptoms.
ROCHESTER, Minn. ― Jan. 27, 2014 ― Mayo Clinic has opened the Mayo Clinic Department of Defense (DOD) Medical Research Office. The office, in Rochester, MN., is designed to be an easy to use single point of contact, linking the research needs of the DOD with Mayo Clinic investigators capable of addressing those needs, and to improve access to funding to serve DOD research and development priorities.
The office oversees Mayo Clinic's portfolio of DOD-funded research, which has evolved over Mayo’s long and successful partnership with the U.S. government. Today, dozens of Mayo Clinic researchers receive funding for special projects that use new technologies and innovative solutions to support military readiness, functional restoration and rehabilitation after complex injuries, restore health and improve wellness of military populations.
“This is a continuation of Mayo Clinic’s 150-year legacy with the DOD,” says Peter Amadio, M.D., director of the office, and an orthopedic surgeon at Mayo Clinic. “The office and website are designed to strengthen this long-standing relationship and to not only match DOD research needs with the expertise of Mayo Clinic, but also accelerate the entire process from proposal development to funding to delivery of a completed project.
ROCHESTER, Minn. — Research has shown that the intestinal microbiome plays a large role in the development of Type 1 diabetes. Now, researchers at Mayo Clinic have demonstrated that gluten in the diet may modify the intestinal microbiome, increasing incidences of Type 1 diabetes. The research was published Nov. 13, in the journal PLOS ONE.
MULTIMEDIA ALERT: Click here to retrieve video and photography from the Mayo Clinic News Network.
These researchers demonstrated that mice fed a gluten-free diet had a dramatically reduced incidence of Type 1 diabetes. These mice were non-obese diabetic mice, or mice that grow to develop Type 1 diabetes. The gluten-free diet worked to protect the mice against Type 1 diabetes. When the researchers added gluten back into the diets of mice it reversed the protective effect the gluten free diet had provided. There also was a measurable impact of the gluten on the bacterial flora of the mice that might be one way in which gluten could affect the risk for diabetes.
"These changes suggest that the presence of gluten is directly responsible for the diabetes-creating effects of diet and determines the gut microflora," says Govindarajan Rajagopalan, Ph.D., a Mayo Clinic immunologist and study author.
ROCHESTER, Minn. — Oct. 14, 2013 — Patients with inflammatory bowel disease are at an increased risk of stroke and heart attack according to a new study presented by Mayo Clinic researchers at the American College of Gastroenterology's Annual Scientific Meeting, Oct. 11–16, in San Diego.
More than 1.5 million Americans have Crohn's disease or ulcerative colitis , the most common forms of inflammatory bowel disease (IBD). Both conditions inflame the lining of the intestine, leading to bouts of watery diarrhea, rectal bleeding, abdominal cramps and pain, fever and weight loss.
ROCHESTER, Minn. — Oct. 14, 2013 — Physical activity is associated with a reduced risk of esophageal cancer, according to a new study presented by Mayo Clinic researchers at the American College of Gastroenterology's Annual Scientific Meeting, Oct. 11–16, in San Diego.
Esophageal cancer is the sixth most common cancer in men worldwide. Early detection and prevention are critical to survival because most patients do not survive the first year of diagnosis, and only 15 percent of patients survive more than five years.
In an analysis of four studies, researchers observed a 32 percent lower risk of esophageal adenocarcinoma in people who were physically active. The analysis also showed the overall risk of esophageal cancer was 19 percent lower among the most physically active people, compared with the least physically active.
ROCHESTER, Minn. — Aug. 19, 2013 — The Mayo Clinic Business Accelerator has already filled all offices, with Boston Scientific, Clear Vision Consulting, Icon Venture Partners and Imanis Life Sciences as the newest tenants. It also has started a publicly available website as a resource for people considering entrepreneurship. In addition, the Accelerator will become a venue for special events and discussion groups led by business leaders.
The Accelerator opened just five months ago and has 16 tenants, including start-up companies and venture capitalists. Three MBA students also have been housed in the Accelerator to work with the start-ups. All offices are rented on a month-to-month basis. Besides offices, the Accelerator has shared work spaces, some still available for leasing.
ROCHESTER, Minn. — October 19, 2012. Statins, a cholesterol lowering drug, may lower the risk of esophageal cancer, especially in patients with Barrett's esophagus, Mayo Clinic researchers report in a study being presented at the American College of Gastroenterology annual meeting. There are two main types of esophageal cancer: squamous cell carcinoma and adenocarcinoma. Barrett's esophagus, a complication of gastroesophageal reflux disease, raises the risk of adenocarcinoma, the more common type of esophageal cancer. Barrett's esophagus is a precancerous condition in which the lining of the esophagus, the tube that carries food from the throat to the stomach, is damaged by stomach acid.
MULTIMEDIA ALERT: A video interview with Dr. Singh is available for journalists to download on the Mayo Clinic News Network.
Although still uncommon, adenocarcinoma is on the rise in the United States. About 16,000 people are diagnosed with esophageal cancer annually, of which more than 60 percent are adenocarcinomas. Only 1 in 5 patients with this cancer will still be alive five years after diagnosis.
"Unfortunately, survival rates for this cancer are low, so prevention is critical," says Siddharth Singh, M.B.B.S., a Mayo Clinic gastroenterologist and study author. "So these results are supporting and encouraging, but more research is needed before we recommend that patients at risk of esophageal cancer take statins."
The Mayo study combined data from 13 studies that included over 1.1 million patients, of which 9,285 had esophageal cancer. The analysis found statins lowered cancer risk by nearly one-third; the longer a patient was on statins, the greater the protective effect.
Researchers also looked at aspirin's effect on reducing the risk of esophageal cancer. When researchers looked specifically at Barrett's esophagus, patients taking a statin and aspirin reduced their risk of esophageal cancer by 72 percent.
The results, researchers say, support a protective association between statin use and esophageal cancer. Given the high mortality rates of the cancer, researchers say these results support randomized trials to evaluate statins in patients who are at high risk of developing esophageal cancer.
NOTE: UPDATED EMBARBO TIME OF 8AM ET
ROCHESTER, Minn. — October 17, 2012. Clostridium difficile infections are becoming more common and more severe in hospitalized children and the elderly, in large part due to greater use of antibiotics, Mayo Clinic researchers report in studies being presented at the American College of Gastroenterology annual meeting. The bacterium, also known as C. difficile or C. diff, can cause an infection with symptoms ranging from diarrhea to life-threatening inflammation of the colon. It is the most common cause of diarrhea in hospitals and is linked to 14,000 U.S. deaths each year.
MULTIMEDIA ALERT: A video interview with Dr. Khanna is available for journalists to download on the Mayo Clinic News Network.
The Mayo study analyzed five years of data from the National Hospital Discharge Survey and found that of an estimated 13.7 million hospitalized children, the 46,176 with C. diff infections had significantly longer hospital stays, more instances of colectomy (partial or total removal of the colon), increased admission to long or short-term care facilities, and higher risk of death.
"Despite increased awareness of C. difficile in children, and advancements in management and prevention, this remains a major problem in hospitalized children," says Sahil Khanna, M.B.B.S., a Mayo Clinic gastroenterologist.
Elderly patients also have a greater risk of complications from C. difficile and dying from the infection. In a separate study of 1.3 million adult patients hospitalized with C. diff, patients over 65 were in the hospital longer, sent to nursing homes more frequently and had a greater risk of death. That suggests being over age 65 is an independent risk factor for adverse outcomes associated with the infection.
Researchers say increased use of antibiotics is a main reason for the increasing infection rates. When a person takes antibiotics, good bacteria or flora that protect against infection are destroyed. When these bacteria are destroyed, patients are vulnerable to C. difficile picked up from contaminated surfaces or spread from a health care provider's hands.
Treatments depend on the severity and number of times a patient has had a C. diff infection. Typically, physicians will treat it with the antibiotic metronidazole or oral vancomycin. For severe cases and patients with recurrent C. diff, fecal transplants are an option. Stool transplant restores healthy intestinal bacteria by placing donor stool in the colon.
Recurrent C. difficile is a major problem with the risk of recurrence being 20 percent after a first infection and as much as 60 percent after multiple infections. People who have had C. difficile are twice as likely to get it again. Other known risk factors include proton-pump inhibitors for gastric reflux, immunosuppression, and long hospital stays.
It costs at least $1 billion annually to treat C. difficile infections.
ROCHESTER, Minn. — July 30, 2012. Roughly 1.8 million Americans have celiac disease, but around 1.4 million of them are unaware that they have it, a Mayo Clinic-led analysis of the condition's prevalence has found. Meanwhile, 1.6 million people in the United States are on a gluten-free diet even though they haven't been diagnosed with celiac disease, according to the study published Tuesday in the American Journal of Gastroenterology.
JOURNALISTS: For multimedia resources including video interviews with study authors, visit the Mayo Clinic News Network.
Researchers have estimated the rate of diagnosed and undiagnosed celiac disease at similar levels prior to this study, but this is the most definitive study on the issue. "This provides proof that this disease is common in the United States," says co-author Joseph Murray, M.D., a Mayo Clinic gastroenterologist. "If you detect one person for every five or six (who have it), we aren't doing a very good job detecting celiac disease."
Celiac disease is a digestive disorder brought on when genetically susceptible people eat wheat, rye and barley. A gluten-free diet, which excludes the protein gluten, is used to treat celiac disease. Roughly 80 percent of the people on a gluten-free diet do so without a diagnosis of celiac disease.
There are a lot of people on a gluten-free diet, and it's not clear what the medical need for that is," Dr. Murray says. "It is important if someone thinks they might have celiac disease that they be tested first before they go on the diet.
To determine its prevalence, researchers combined blood tests confirming celiac disease with interviews from a Centers for Disease Control and Prevention (CDC) nationwide population sample survey called National Health and Nutrition Examination Survey. The survey, designed to assess the health and nutrition of U.S. adults and children, is unique in that it combines interviews and physical examinations.
Researchers found that celiac disease is much more common in Caucasians.
"In fact, virtually all the individuals we found were non-Hispanic Caucasians," says co-author Alberto Rubio-Tapia, M.D., a Mayo Clinic gastroenterologist. But previous research in Mexico has shown that celiac disease could be just as common as it is in the U.S.